

CLIA #: 31D2026917


PATIENT DEMOGRAPHICS

PATIENT INFORMATION:	PHYSICIAN INFORMATION:	SPECIMEN INFORMATION:
Patient, Test DOB: 1/1/1960 Gender/Age: M/66	Test Physician, MD Test Practice 300 Columbus Circle Suite A, Edison, NJ 08837 (866) 909-7284, Fax:(908) 272-1478	ACCESSION #: TS26-0029X PROCEDURE DATE: 4/19/2026 DATE RECEIVED: 4/20/2026 REPORTED ON: 4/20/2026


CLINICAL INFORMATION

PSA Level = 4.66 ng/mL as provided; Elevated PSA; Normal DRE; (actual clinical stage will depend on referring physician's evaluation) Clinical Stage: T1c assumed, (actual clinical stage will depend on referring physician's evaluation), ICD-10: R97.20

ULTRA SOUND GUIDED NEEDLE BIOPSIES



MRI FUSION BIOPSIES



DIAGNOSIS SUMMARY (USG BIOPSIES)

Specimen	Diagnosis	CGS*	GG**	PTI
A	Malignant	7(3+4)	2	40%
B	Malignant	7(3+4)	2	50%
F	Malignant	6(3+3)	1	10%
H	Malignant	6(3+3)	1	<5%
J	Malignant	6(3+3)	1	<5%
D	ASAP			
M	ASAP			

*CGS: Composite Gleason Score, **Grade Group

DIAGNOSIS SUMMARY (MRI FUSION BIOPSIES)

Specimen	Diagnosis	CGS*	GG**	PTI
P	Malignant	7(3+4)	2	15%
O	Malignant	6(3+3)	1	20%
Q	Malignant	6(3+3)	1	30%

*CGS: Composite Gleason Score, **Grade Group

FINAL DIAGNOSIS (USG BIOPSIES)

- A: PROSTATE, LEFT APEX:**
- Prostatic Adenocarcinoma.
 - Gleason Score 7(3+4); Gleason pattern 4 is 10%.
 - Involving 40% of total surface area, and 1 of 1 core.
 - Perineural invasion not seen.

B: PROSTATE, LEFT LATERAL APEX:

- Prostatic Adenocarcinoma.
- Gleason Score 7(3+4); Gleason pattern 4 is 5%.
- Involving 50% of total surface area, and 2 of 2 cores.
- Perineural invasion not seen.

C: PROSTATE, LEFT MID:

- Benign prostatic tissue.

D: PROSTATE, LEFT LATERAL MID:

- Focus of atypical glands, suspicious for malignancy.

E: PROSTATE, LEFT BASE:

- Benign prostatic tissue.

F: PROSTATE, LEFT LATERAL BASE:

- Prostatic Adenocarcinoma.
- Gleason Score 6(3+3).
- Involving 10% of total surface area, and 1 of 1 core.
- Perineural invasion not seen.

G: PROSTATE, RIGHT APEX:

- Benign prostatic tissue.

H: PROSTATE, RIGHT LATERAL APEX:

- Prostatic Adenocarcinoma.
- Gleason Score 6(3+3).
- Involving <5% of total surface area, and 1 of 1 core.
- Perineural invasion not seen.

I: PROSTATE, RIGHT MID:

- Benign prostatic tissue.

J: PROSTATE, RIGHT LATERAL MID:

- Prostatic Adenocarcinoma.
- Gleason Score 6(3+3).
- Involving <5% of total surface area, and 1 of 1 core.
- Perineural invasion not seen.

K: PROSTATE, RIGHT BASE:

- Benign prostatic tissue.

L: PROSTATE, RIGHT LATERAL BASE:

- Benign prostatic tissue.

M: PROSTATE, LEFT ANTERIOR:

- Focus of atypical glands, suspicious for malignancy.

N: PROSTATE, RIGHT ANTERIOR:

- Benign prostatic tissue.

FINAL DIAGNOSIS (MRI FUSION BIOPSIES)

O: PROSTATE, LEFT APEX, MRI/TRUS FUSION:

- Prostatic Adenocarcinoma.
- Gleason Score 6(3+3).
- Involving 20% of total surface area, and 1 of 1 core.
- Perineural invasion not seen.


P: PROSTATE, LEFT LATERAL BASE, MRI/TRUS FUSION:

- Prostatic Adenocarcinoma.
- Gleason Score 7(3+4); Gleason pattern 4 is 5%.
- Involving 15% of total surface area, and 14 of 24 cores.
- Perineural invasion present.
- Tumor involves up to 50% and 0.6 cm in the most extensively-involved core.


Q: PROSTATE, LEFT ANTERIOR, MRI/TRUS FUSION:

- Prostatic Adenocarcinoma.
- Gleason Score 6(3+3).
- Involving 30% of total surface area, and 6 of 11 cores, discontinuously.
- Perineural invasion not seen.
- Tumor involves up to 85% and 1.5 cm discontinuously in the most extensively-involved core.

IMAGES




A. Adenocarcinoma, Gleason score 7(3+4)



A. PIN2 stain

PARTIN TABLE*

G Score: 7(3+4) **PSA:** 4.66 ng/mL **Clinical Stage:** T1c



95% confidence intervals shown in parentheses

KEY OC - Organ Confined Disease SV+ - Seminal Vesicle Involvement
 EPE - Extra-Prostatic Extension LN+ - Lymph Nodal Involvement

* James Buchanan Brady Urological Institute, Johns Hopkins Medicine
 (<http://urology.jhu.edu/prostate/partintables.php>)

COMMENTS

Specific immunostains CK34βE12 and P504S (AMACR) were performed on specimens A, H, J and O and the results support the above diagnosis.

Part A has been reviewed in consultation with Test Physician, MD who concurs with the above diagnosis.

Results of PTEN and ERG immunohistochemical prostate cancer risk stratification (specimen A):

PTEN: Intact

ERG: Negative

Interpretation: Intermediate risk

PTEN immunohistochemical stain shows intact expression and ERG stain is negative. This immunophenotype is associated with intermediate prognosis and risk of biochemical recurrence in comparison to adenocarcinomas of similar Gleason score.

References: A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer. J Natl Cancer Inst (2016): 108(2):djv346

The new five-tiered prostate Grade Group system, as adopted by WHO, is defined such that each group is associated with a unique prognosis based on PSA biochemical recurrence as an endpoint.

- Grade Group 1: Gleason Score <= 6
- Grade Group 2: Gleason Score 7(3+4)
- Grade Group 3: Gleason Score 7(4+3)
- Grade Group 4: Gleason Score 8
- Grade Group 5: Gleason Scores 9-10

In a large (>3500 patients) single institutional study, the 5-year actuarial biochemical recurrence-free survival for biopsy Grade Groups 1-5 were 94.2%, 89.2%, 73.1%, 63.1%, and 54.7%, in patients treated with radical prostatectomy.

A contemporary prostate cancer grading system: a validated alternative to the Gleason Score. Eur Urol. 2016;69(3):428-35. Independent surgical validation of the new prostate cancer Grade-Grouping system. BJU Int. 2016;118(5):763-769.

GROSS EXAMINATION (USG BIOPSIES)							
SPECIMEN	CORES	LENGTH	INK	SPECIMEN	CORES	LENGTH	INK
A: LEFT APEX	1	1.7 cm		I: RIGHT MID	1	1.5 cm	
B: LEFT LATERAL APEX	2	0.6,0.7 cm	Green	J: RIGHT LATERAL MID	2	0.8, 0.8 cm	Green
C: LEFT MID	2	0.6,0.6 cm		K: RIGHT BASE	1	1.6 cm	
D: LEFT LATERAL MID	2	0.5,1.2 cm	Green	L: RIGHT LATERAL BASE	2	0.5, 0.8 cm	Green
E: LEFT BASE	2	0.8,0.8 cm		M: LEFT ANTERIOR	1	1.3 cm	
F: LEFT LATERAL BASE	1	0.8 cm	Green	N: RIGHT ANTERIOR	2	0.6,0.8 cm	Green
G: RIGHT APEX	1	1.1 cm		O: LEFT APEX, MRI/TRUS FUSION	1.5	1.5 cm	
H: RIGHT LATERAL APEX	1	1.4 cm	Green	P: LEFT LATERAL BASE, MRI/TRUS FUSION	25	0.3-1.6 cm	Green
				Q: LEFT ANTERIOR, MRI/TRUS FUSION	15	0.3-1.7 cm	

A positive control for each stain has been reviewed and accepted.

Any immunostain(s) used were validated and their performance characteristics determined by LabGenomics. They may not be cleared or approved by the U. S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research. This laboratory has been approved by CLIA 88, designated as a high-complexity laboratory and is qualified to perform these tests.